StockData
Impact BioMedical Inc. logo

Impact BioMedical Inc. (IBO) company profile

IBONYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$3.06+0.38 (+14.18%)

Close on Oct 19, 2026Market cap $329.93MP/E –Yield –

About Impact BioMedical

Pharmaceutical Preparations, SIC 2834

Impact BioMedical Inc. is a biotechnology company focused on the discovery, development, and patenting of science and technologies for human healthcare and wellness. The company operates in a single biotechnology business segment, targeting the prevention, inhibition, and treatment of neurological, oncological, and inflammatory conditions, as well as infectious diseases. Key product candidates and platforms include Linebacker for oncology and inflammatory disorders, Laetose as a low-glycemic alternative sugar formulation, Equivir for antiviral applications, and the 3F suite of functional fragrances. Its commercialization strategy centers on licensing and partnering with pharmaceutical, food, and consumer packaged goods companies.

The company operates primarily through subsidiaries such as Global BioLife, Impact BioLife Science, Global BioMedical, and Sweet Sense. Its corporate headquarters are located in Houston, Texas. Impact BioMedical maintains intellectual property portfolio rights consisting of sixty-nine issued patents and more than sixty pending patent applications worldwide.

Summary of the business section of Impact BioMedical's latest annual report, written by StockData.

Company profile

Company

Legal name
Impact BioMedical Inc.
Founded
2018
Headquarters
West Henrietta, NY
Address
275 Wiregrass Pkwy, 14586
Phone
(585) 232-1500
Employees
2, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
GRASSI & CO., CPAs, P.C., Jericho, New York

Stock & identifiers

Ticker
IBO
Exchange
NYSE
IPO date
Sep 16, 2024
Shares outstanding
108M, Aug 4, 2026
Public float
$7.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1834105
CUSIP
04529L106
ISIN
US04529L1062
FIGI
BBG01JFZG014
Share class FIGI
BBG01JFZG023
EIN
85-3926944

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Frank D. HeuszelChief Executive Officer, Director97,344
Mark SuseckChief Operating Officer32,112
Todd D. MackoChief Financial Officer16,462
Castel Berisford HibbertDirector32,112
Heng Fai Ambrose ChanDirector32,112
Jason GradyDirector28,164
Melissa Kaye SimsDirector32,112
David K. KeeneDirector32,112
Christian Thomas ZimmermanDirector32,112
Elise BrownellDirector32,112

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsTotalvs. prior year
Frank D. Heuszel
Chief Executive Officer
$43.71K$11.10K$54.81K–
Mark Suseck
Chief Operating Officer
$126.69K$32.00K$158.69K–
Todd D. Macko
Chief Financial Officer
–$555$555–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“Company currently has two full-time employee and six shared employees with DSS as of December 31, 2025.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 27, 2026Merger voteDefinitive merger proxy statement
Aug 8, 2024ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?